Pfizer- Early Identification and Diagnosis of Non-Alcoholic Steatohepatitis (NASH) in At-Risk Populations – RFP
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire within unit
Memorial Deadline: Thursday 15th, June 2023
External Deadline: Thursday 22nd, June 2023
Description
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: May 4, 2023
Geographic Scope: Global
Clinical Area: Non-Alcoholic Steatohepatitis (NASH)
Link to full RFP: Early Identification and Diagnosis of Non-Alcoholic Steatohepatitis (NASH) in At-Risk Populations
Application Due Date: June 22, 2023
Specific Area of Interest: Projects that will be considered for Pfizer support will focus on educating healthcare professionals, with a focus on general practitioners and non-liver specialists, on NASH to:
- Increase awareness of patients at risk for NASH and enable appropriate and early diagnosis to enable appropriate management to help prevent disease progression
- Establish a call to action to raise awareness of NASH in at risk and underdiagnosed minority and underserved populations with NASH to reduce disparities and delayed diagnosis
Explore strategies that empower patients to play an active role in understanding NASH and decision making regarding available diagnostic and disease management options.
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Jessica Romano, Grant Officer (jessica.romano@pfizer.com).